SkQ1 / Visomitin ophthalmic solution for dry eye syndrome
approvedTreat signs and symptoms of dry eye syndrome and protect the ocular surface from inflammation and corneal damage using a mitochondria-targeted antioxidant.
Topical ophthalmic solution containing SkQ1, evaluated in randomized, double-masked, placebo- or vehicle-controlled dry eye studies and ocular surface cell models.
Vehicle-controlled clinical study of SkQ1 for dry eye syndrome was posted on 2019-12-20; earlier publications reported Phase 2 and multicenter randomized clinical results, and Visomitin was described as registered in Russia for dry eye syndrome.
Clinical publications reported SkQ1/Visomitin was safe and improved dry eye signs and symptoms versus placebo, including corneal fluorescein staining, lissamine green staining, lid margin redness, ocular discomfort, dryness, grittiness, tear film stability, and reduced corneal damage. A sponsored ocular surface study reported anti-inflammatory effects and enhanced corneal epithelial wound healing in cell models.